Tildacerfont/Placebo

DRUG2 trials

Sponsors

Spruce Biosciences

Conditions

Congenital Adrenal Hyperplasia

Phase 2

A Ph2b to Evaluate Clinical Efficacy and Safety of Tildacerfont in Adult CAH

TerminatedNCT04457336

Spruce BiosciencesCongenital Adrenal Hyperplasia

Start: 2020-08-26End: 2024-05-23Updated: 2025-07-08

A Ph2b to Evaluate Tildacerfont in the Reduction of Glucocorticoid Steroid Doses in Adult CAH

TerminatedNCT04544410

Spruce BiosciencesCongenital Adrenal Hyperplasia

Start: 2021-02-22End: 2025-01-31Updated: 2025-10-01